bluuebunny/crossref_metadata_2025_split huggingface dataset:
Abstract 2436: Non canonical activation of Sonic Hedgehog pathway in uterine leiomyosarcoma
Authors: Garcia Natalia , Oliveira Bianca C. , Ferreira Kelly P. , Baracat Edmund C. , Carvalho Katia C. 
Published: July 2017

Abstract
Background: Uterine leiomyoma (ULM) and leiomyosarcoma (ULMS) are smooth muscle tumors with distinct clinical and biological behavior. They can be a cause of infertility and even death. Little is known about the factors that can to influence these tumors behavior and biology. Sonic Hedgehog (SHH) pathway components were previously implicated in the ULMS malignancy risk; however its activation mechanism is unknown. In this study, we investigated the gene expression profile of Sonic Hedgehog Signaling and pathway upstream genes in myometrium (MM), ULM and LMS cell lines.
Methods: Total RNA obtained from cell lines were submitted to cDNA synthesis and quantitative real time PCR (qRT-PCR), using 7500 System (Life Technologies, USA). Gene expression of SHH, PTCH1, SMO, SUFU, GLI 1-3, CCND1, BCL-2 and BMP4 were assessed.
Results: Gene expression data showed an upregulation of SMO, SUFU, GLI1, BCL-2 and BMP4 in LMS cells when compared to MM. GLI1 (RQ=11) and BCL-2 (RQ=20) genes had higher expression. In the other side, SHH, PTCH1, GLI2 and GLI3 showed upregulation in MM cells.
Conclusion: Our results showed that the Sonic hedgehog pathway is activated in LMS cells but by SHH independent form (non-canonical pathway). This could be explained by the downexpression of SHH ligand and the PTCH1 receptor, and by the upexpression of SMO, GLI1 and pathway target genes as BCL-2 and BMP4 in uterine LMS cells compared to LM and MM. These results suggest a new therapeutic perspective for LMS by target drugs to inhibit SMO and GLI1 molecules.
Citation Format: Natalia Garcia, Bianca C. Oliveira, Kelly P. Ferreira, Edmund C. Baracat, Katia C. Carvalho. Non canonical activation of Sonic Hedgehog pathway in uterine leiomyosarcoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 2436. doi:10.1158/1538-7445.AM2017-2436
Abstract 2437: Overexpression of MYL5 promotes cervical cancer cell metastasis through SLUG and HIF-1α signaling
Authors: Zhang Lan 
Published: July 2017

Abstract
Myosin light chains (MLC) serve important regulatory functions in a wide range of cellular and physiological processes. Previous research found that MLC are also chromatin-associated nuclear proteins which regulate gene transcription. In this study, we show that the MLC member myosin regulatory light chain 5 (MYL5) controls metastasis in cervical cancer. We uncover this role of MYL5 through clinical cervical cancer samples and various in vitro and in vivo models of metastasis. MYL5 promotes metastasis by enhancing the transcription of SLUG and hypoxia inducible factor-1α (HIF-1α). Moreover, we reveal a bidirectional regulation between MYL5 and HIF-1α. HIF-1α specifically binds to the MYL5 promoter region, and hypoxia leads to increased levels of MYL5 in cervical cancers. Overexpression of MYL5 sustained HIF-1α expression in normoxic condition. Clinical data confirmed a positive correlation between MYL5 and HIF-1α. In summary, our observations suggest a potential application of MYL5 in prognosis prediction and cancer treatment.
Citation Format: Lan Zhang. Overexpression of MYL5 promotes cervical cancer cell metastasis through SLUG and HIF-1α signaling [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 2437. doi:10.1158/1538-7445.AM2017-2437
Abstract 2440: Cross-tissue interactome analyses unravel novel oncogenic roles of SOX2
Authors: Schaefer Thorsten , Candido Silvia , Wang Hui , Bock Thomas , Schmidt Alexander , Lengerke Claudia 
Published: July 2017

Abstract
First recognized for its significance in early embryogenesis, SOX2 (sex determining region Y box 2) more recently received major attention as a (i) transcriptional master regulator of stemness driving the re-programming of terminally differentiated somatic cells back into a pluripotent stem cell state and (ii) powerful oncogene of the cancer stem cell (CSC) compartment. We and others have shown that SOX2 expression relies on canonical PI3K/AKT signaling involving direct physical contact and phospho-modification by AKT. Interestingly, we observed that these interactions are highly tissue specific which prompted us to perform a systematic proteomic analysis of co-factors regulating SOX2 biology.
The SOX2 interactome was analyzed in human breast carcinoma and glioblastoma cell lines by co-immunoprecipitation (co-IP) and HPLC/MS revealing &gt;900 individual and &gt;70 conserved proteinaceous co-factors, thus underscoring a hitherto underestimated scaffolding function of SOX2. As expected, a major proportion of binding partners cluster in functional categories implicated in DNA binding and/or nucleotide modification (e.g. helicases, transferases, and ligases). However, a near equal share of SOX2 associated factors fall into functional classes formally unrelated to transcription modulation such as cell adhesion, cytoskeletal organization, or metabolic adaptation. Using SOX2 knock-down and overexpression cells generated by lentiviral technology, we confirm co-regulation of SOX2 with selected binding partners. Moreover, we observe co-depletion of SOX2 and protein co-factors in cells of stalled AKT activity, and a molecular restoration of both upon proteasomal inhibition.
We conclude that, besides its known significance in DNA activity control, the SOX2 protein engages in various interactions seemingly unrelated to transcription modulation. These newly discovered interactions are likely to synergize with canonical SOX2 functions (i.e. the induction and maintenance of stemness), but involve regulation at post-translational level and of extra-nuclear components. Our efforts thus add an exciting new facet to SOX2 biology and eventually, may open new therapeutic avenues for targeted anti-CSC therapy.
Citation Format: Thorsten Schaefer, Silvia Candido, Hui Wang, Thomas Bock, Alexander Schmidt, Claudia Lengerke. Cross-tissue interactome analyses unravel novel oncogenic roles of SOX2 [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 2440. doi:10.1158/1538-7445.AM2017-2440
Abstract 246: Assessing microbial dysbiosis of electronic cigarettes and cigarette smokers using oral and lung microbiome
Authors: Ying Kevin , Song Min-Ae , Weng Daniel Y. , Nickerson Quentin , Frankhouser David , Yan Pearlly S. , Bundschuh Ralf , Wewers Mark D. , Mathé Ewy , Freudenheim Jo L. , Shields Peter G. 
Published: July 2017

Abstract
The link between smoking tobacco and changes in the oral microbiome in response to tobacco smoking are well established. It is not known if there are changes in response to electronic cigarettes (e-cig). These changes in the microbiome are associated with increased numbers of disease causing pathogens. Currently there are no published studies that have investigated the relationship of smoking tobacco on both the oral and lung microbiome. There is insufficient evidence showing whether changes in oral cavity and lung microbiome are also seen in e-cig users. We will study the oral cavity and lung of non-smokers, smokers and e-cig users to examine concordance between oral cavity and the lungs as well as comparing the three groups, examining the microbiomes and expression of inflammatory markers. We hypothesize that microbial dysbiosis and expression of inflammatory cytokines will differ for smokers and non-smokers; and that e-cig users will have microbial dysbiosis similar to cigarette smokers. A cross-sectional study is being conducted on three groups, 1) never-smokers, 2) cigarette smokers, and 3) e-cig users. For each study participant, saliva and bronchoalveolar lavage (BAL) are being collected to measure microbiome. RNA is extracted from saliva and BAL samples for total transcriptome analysis using RNA-seq. This analysis will detect human and bacterial reads thereby allowing observations of bacterial communities as well as human inflammatory cytokine response to bacterial presence. 85% to 98% of BAL sample reads aligned to the human genome compared to less than 50% from saliva samples. The alignment results allow us to deduce that the majority of reads from BAL samples are human and that the majority of the reads in saliva samples are bacterial.
Preliminary results show detection of human RNA expression and of bacterial reads are present in both saliva and BAL samples. More samples are being processed and the comparison of BAL and saliva samples between the three groups will be discussed.
Citation Format: Kevin Ying, Min-Ae Song, Daniel Y. Weng, Quentin Nickerson, David Frankhouser, Pearlly S. Yan, Ralf Bundschuh, Mark D. Wewers, Ewy Mathé, Jo L. Freudenheim, Peter G. Shields. Assessing microbial dysbiosis of electronic cigarettes and cigarette smokers using oral and lung microbiome [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 246. doi:10.1158/1538-7445.AM2017-246
Abstract 2460: Copy number alterations in NOTCH2 and PTP4A3 are associated with prognosis and support novel therapeutic strategies for malignant pleural mesothelioma
Authors: Leon Leticia G. , Gemelli Maria , Zucali Paolo A. , Zoumadakis Christos , Giovannetti Elisa 
Published: July 2017

Abstract
Malignant pleural mesothelioma(MPM) is an aggressive cancer, which incidence has constantly increased over the past two decades and is expected to peak in 2020. The overall prognosis is poor, and predictive biomarkers of drug activity are missing. Given the heterogeneous and complex nature of MPM, it is likely that genomic aberrations changing the expression of several genes, might affect therapeutic response. Therefore, the aim of the present study was to identify genes whose copy number alterations might predict the MPM prognosis.
Recurrent copy number alterations of genes were analyzed by high-resolution whole-genome sequencing in DNA obtained from a “discovery cohort” of 26 resected MPM patients treated with pemetrexed-based chemotherapy (8 with progressive disease, vs. 10 with stable disease and 8 with partial response). Prognostic markers identified by Copy Number Variation analysis with Nexus, Control-FREEC and ReadDepth software were validated by PCR gene copy number and gene expression analyses both in the “discovery” and in two “validation” cohorts of pemetrexed-treated and untreated patients (N=45 and 40). The role of emerging genes was evaluated through siRNA and pharmacological studies using proliferation, migration and apoptosis assays in MPM cells.
As reported previously we observed copy number loss of CDKN2A (15.4%) and BAP1 (7.7%). Interestingly, copy number gain of NOTCH2 was observed in 50% of samples of the patients who underwent progression, whereas losses of PTP4A3 were associated with clinical benefit (SD+PR). The prognostic relevance of NOTCH2 was confirmed by PCR analysis. NOTCH-2 silencing reduced MPM cell migration and enhanced apoptosis induction by pemetrexed, while a PTP4A3 inhibitor overcame pemetrexed resistance in MPM cells characterized by high NOTCH2 and PTP4A3 expression.
These results support the role of NOTCH2 as a novel prognostic/predictive biomarker for MPM, prompting prospective randomized trials for its validation. Moreover, preclinical data suggest that NOTCH2 and PTP4A3 are oncogenes suitable for effective therapeutic targeting in pemetrexed-resistant MPM cells.
Citation Format: Leticia G. Leon, Maria Gemelli, Paolo A. Zucali, Christos Zoumadakis, Elisa Giovannetti. Copy number alterations in NOTCH2 and PTP4A3 are associated with prognosis and support novel therapeutic strategies for malignant pleural mesothelioma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 2460. doi:10.1158/1538-7445.AM2017-2460
Abstract 2464: Papillary renal cell carcinoma, proposal of a new classification system based on integrated molecular, histological and clinical analysis
Authors: Saleeb Rola , Farag Mina , Brimo Fadi , Rotondo Fabio , Plant Pamela , Yousef George 
Published: July 2017

Abstract
Background:
Papillary Renal Cell Carcinoma (PRCC) is divided into histological subtypes 1 and 2. Type 2 is known to have worse clinical behavior. A number of PRCC cases (~ 50%), fail to meet all reported morphological criteria for either type, hence are best characterized as PRCC not otherwise specified (NOS). There are yet no reliable markers to resolve the PRCC NOS category. That in turn reflects the clinical dilemma of how to manage these patients.
Experimental Design:
PRCC patient cohort of 115 cases was selected for the study. Cases were subtyped histologically into PRCC types 1, 2 and NOS. Potentially distinguishing markers ABCC2, CA9, SAll4, and BCL2 selected from our previous genomic analysis, were assessed by immunohistochemistry (IHC). A total of 24 cases were further selected for molecular analysis using miRNA expression and copy number variation (CNV). Univariate and multivariate survival analysis were performed using Log rank test and cox proportionate hazards.
Results:
Markers ABCC2, CA9 exhibited distinct staining patterns between the two classic PRCC subtypes; and successfully classified many of the PRCC NOS (45%) cases. Moreover, immunomarkers revealed a third distinct subtype of PRCC (35% of the PRCC cohort). Molecular
testing using miRNA expression and CNV analysis confirmed the presence of three distinct molecular signatures corresponding to the 3 subtypes. On univariate analysis DFS was significantly enhanced in the type1 versus 2& 3 (p value 0.047). PRCC subtyping retained
significance on multivariate analysis (p value 0.025, HR:6, 95% CI 1.25 to 32.2) .
Conclusion:
We propose a new classification system of PRCC integrating morphological, immunophenotypical, and molecular analysis. Our classification reveals a 3rd PRCC subtype that was not previously described. This subtype has overlapping morphology of with PRCC types 1 and 2, hence would be subtyped as PRCC NOS in the current classification. Molecularly PRCC type 3 has a distinct signature and clinically it behaves similar to PRCC type 2. The new classification stratifies PRCC patients into clinically relevant subgroups and has significant future implications on the management of PRCC.
Citation Format: Rola Saleeb, Mina Farag, Fadi Brimo, Fabio Rotondo, Pamela Plant, George Yousef. Papillary renal cell carcinoma, proposal of a new classification system based on integrated molecular, histological and clinical analysis [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 2464. doi:10.1158/1538-7445.AM2017-2464
Abstract 2471: Role of PALB2-BRCA1 interaction in tumor suppression
Authors: Mahdi Amar H. , Huo YanYing , Xia Bing 
Published: July 2017

Abstract
Homologous recombination (HR) is the only error-free pathway for the repair of DNA double strand breaks (DSBs). BRCA1 and BRCA2, the two major breast cancer suppressor proteins, play essential roles in HR-mediated repair of DSBs by promoting the recruitment of RAD51, the recombination enzyme, to DNA damage sites for the initiation of HR. PALB2 (partner and localizer of BRCA2) plays a key role in this pathway by acting as a chromatin adaptor for BRCA2 and a linker between BRCA1 and BRCA2. Like BRCA1 and BRCA2, PALB2 is a tumor suppressor gene itself. Germline, heterozygous mutations in the gene increase the risk of breast, ovarian and pancreatic cancers. However, its mechanism is not fully understood. To investigate the in vivo role of the PALB2-BRCA1 interaction, we previously generated a Palb2 knockin mouse strain which contains a mutation that disrupts BRCA1 binding. This mouse model also allows us to bypass the embryonic lethality of the Palb2 KO mice. In this study, we hypothesized that the direct communication between the two proteins is critical for proper DNA damage repair and response in vivo and for suppression of tumorigenesis. Indeed, both immunohistochemistry (IHC) and immunofluorescence (IF) demonstrated that different tissues of the mutant mice have higher levels of endogenous DSBs (γH2AX foci) and slower DSB repair kinetics after ionizing radiation (IR). Yet, mutant cells were more resistant to cell death. When aged under normal conditions, mutant mice showed increased tumor incidence in multiple tissues, particularly in the liver. When challenged by IR, mutant mice quickly developed thymic lymphoma and later in other tissues including liver and ovary, etc. Interestingly, when crossed with Trp53 mutant mice, the resulting Palb2m/m;Trp53+/- mice showed greatly accelerated development of thymic lymphoma and osteosarcoma, which are typically associated with Trp53 but not Palb2 mutations. Exome sequencing revealed focal deletion of the wild-type allele of Trp53 in the majority of the tumors, suggesting that disruption of BRCA1-PALB2/BRCA2 axis promotes regional genomic deletions that may lead to loss of other tumor suppressors such as p53. Our results underscore the importance of the BRCA1-PALB2/BRCA2 pathway for tumor suppression and suggest a potentially novel mechanism for BRCA1/PALB2-mediated tumor suppression, which is by preventing Trp53/TP53 loss of heterozygosity (LOH), which allows for tumor development.
Citation Format: Amar H. Mahdi, YanYing Huo, Bing Xia. Role of PALB2-BRCA1 interaction in tumor suppression [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 2471. doi:10.1158/1538-7445.AM2017-2471
Abstract 2477: Genomic instability in BRCA1-deficient cells is a result of the anti-recombinogenic activity of BLM helicase
Authors: Patel Dharm S. , Misenko Sarah M. , Bunting Samuel F. 
Published: July 2017

Abstract
Mutations in BRCA1 are responsible for approximately 5% of cases of breast cancer, and there are few treatment options that substantially alter the probability of disease onset in individuals with BRCA1 mutations. BRCA1-deficient cells exhibit increased genomic instability following DNA damaging treatments due to a defect in the homologous recombination (HR) DNA repair pathway. Presently, Olaparib, a PARP inhibitor, is approved as a targeted monotherapy for germline BRCA1 mutated advanced ovarian cancers. As use of this treatment has expanded, data suggests that patients exhibit a further relapse and resistance to PARP inhibitors via mechanisms that include the development of secondary BRCA1 reversion mutations, enhanced drug efflux relating to P-glycoprotein, and mutations in other DNA repair proteins that restore HR. Here, we show that the RECQ helicase, BLM, mediates the genomic instability observed in BRCA1-deficient cells by a mechanism that depends in part on its anti-recombinogenic activity. We have generated conditional knockout mice with single and combined deficiencies in BRCA1, BLM, and 53BP1 in the B lymphocyte cell population. Ablation of BLM in BRCA1-deficient cells allows the HR repair pathway to be restored, leading to a partial rescue of the genomic instability that is present in BRCA1-deficient cells. The stable accumulation of RAD51, a marker for HR, at DNA double-strand break sites is inhibited by BLM in BRCA1-deficient B cells. However, DNA end resection is not impacted by single or co-deletion of BRCA1 and BLM. Furthermore, cells co-deficient in BRCA1 and BLM display limited sensitivity to PARP inhibition. The rescue in HR and PARPi sensitivity phenotypes following deletion of BLM is only present in hypomorphic BRCA1Δ11/Δ11 cells and not the RING domain deficient BRCA1Δ2/Δ2. These results demonstrate that the anti-recombinogenic activity of BLM is of potentially great significance for regulating the balance of HR versus other error-prone repair pathways. Mutation of BLM in BRCA1-deficient tumors is therefore a potential pathway leading to resistance to PARPi and other DNA damaging agents.
Citation Format: Dharm S. Patel, Sarah M. Misenko, Samuel F. Bunting. Genomic instability in BRCA1-deficient cells is a result of the anti-recombinogenic activity of BLM helicase [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 2477. doi:10.1158/1538-7445.AM2017-2477
Abstract 2480: Suppression of homology-dependent DNA double-strand break repair induces PARP inhibitor sensitivity in VHL-deficient human renal cell carcinoma
Authors: Scanlon Susan E. , Sulkowski Parker L. , Glazer Peter M. 
Published: July 2017

Abstract
The von Hippel-Lindau (VHL) tumor suppressor gene is inactivated in the vast majority of human clear cell renal carcinomas. The pathogenesis of VHL loss is currently best understood to occur through stabilization of the hypoxia-inducible factors, activation of hypoxia-induced signaling pathways, and transcriptional reprogramming towards a pro-angiogenic and pro-growth state. However, hypoxia also drives other pro-tumorigenic processes, including the development of genomic instability via down-regulation of DNA repair gene expression. Here, we find that DNA repair genes involved in double-strand break repair by homologous recombination (HR) and in mismatch repair, which are down-regulated by hypoxic stress, are decreased in VHL-deficient renal cancer cells relative to wild type VHL-complemented cells. Non-homologous end joining (NHEJ) genes are not decreased in VHL-deficient cells, demonstrating specificity of the down-regulation and similarity to hypoxia. Functionally, this repression of HR genes is associated with impaired DNA double-strand break repair in VHL-deficient cells, as determined by the persistence of ionizing radiation-induced DNA double-strand breaks and reduced activity in a homology-dependent plasmid reactivation assay. Furthermore, VHL deficiency conferred increased sensitivity to the DNA crosslinking agent mitomycin C and PARP inhibitors, analogous to the synthetic lethality observed between hypoxia and these chemotherapeutic agents. Finally, we discovered a correlation between VHL inactivation and reduced HR, but not NHEJ, gene expression in a large panel of human renal carcinoma samples. Together, our data elucidate a novel connection between VHL-deficient renal carcinoma and hypoxia-induced down-regulation of DNA repair, and identify potential opportunities for targeting DNA repair defects in human renal cell carcinoma.
Citation Format: Susan E. Scanlon, Parker L. Sulkowski, Peter M. Glazer. Suppression of homology-dependent DNA double-strand break repair induces PARP inhibitor sensitivity in VHL-deficient human renal cell carcinoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 2480. doi:10.1158/1538-7445.AM2017-2480